HIGHLIGHTS
- who: Neelu Puri from the University of Biomedical Sciences, of Illinois at Rockford, Rockford, USA have published the research: EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer, in the Journal: (JOURNAL)
- what: In a recent update to this study OS was reported, which demonstrated a survival increase of 3 years for gefitinib treated NSCLC patients with EGFR mutations. Many of these studies involve drugs that are in phase I clinical trials, in which the overall goal is to overcome acquired resistance.
- future: Future studies in this direction could be . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.